|
|
| Education |
| 1993 |
|
Postdoctoral Research Fellow |
|
|
|
University of North Carolina, Chapel Hill, NC. |
| 1991 |
|
Ph.D. |
|
Molecular Biology |
|
University of Pittsburgh, Pittsburgh, PA |
| 1984 |
|
A.B. |
|
Biology/Art |
|
Middlebury College, Middlebury, VT |
| Professional Experience |
| 2006- PRES |
Associate Professor, Department of Molecular Virology, Immunology and Medical Genetics, The Ohio State University School of Medicine, Columbus, Ohio. |
| 2006- PRES |
Associate Professor, Department of Pediatrics, Division of Molecular Medicine, The Ohio State University School of Medicine, Columbus, Ohio |
| 1999- PRES |
Member, Comprehensive Cancer Center, James Cancer Hospital, Solove Research Institute, The Ohio State University, Columbus, Ohio |
| 1999- PRES |
Principal Investigator, Center for Gene Therapy, The Research Institute at Nationwide Children's Hospital, Columbus, OH. |
| 2000- 2006 |
Assistant Professor, Department of Melecular Virology, Immunology and Medical Genetics, The Ohio State University School of Medicine, Columbus, OH. |
| 1999- 2006 |
Assistant Professor, Department of Pediatrics, Division of Molecular Medicine, The Ohio State University School of Medicine, Columbus, OH. |
| 1995- 1999 |
Research Assistant Professor, Gene Therapy Center, The University of North Carolina School of Medicine, Chapel Hill, NC. |
| 1993- 1995 |
Senior Research Associate, Gene Therapy Center, University of North Carolina at Chapel Hill, Chapel Hill, NC. |
| 1991- 1993 |
Postdoctoral Research Fellow, Department of Biochemistry and Biophysics, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC. |
BARTLETT LABORATORY STAFF
|
Principal Investigator:
Jeffrey S. Bartlett, Ph.D.
|
|
|
|
|
| Selected Publications |
| Zaiss, A.K., Cotter, M.J., White, L.R., Clark, S.A., Wong, C.W., Holers, V.M., Bartlett, J.S., and Muruve, D.A. Complement is an essential component of the immune response to adeno-associated virus vectors. J Virol. 2008 Mar;82(6):2727-40. Epub 2008 Jan 16. [PMID: 18199646] PubMed ID: 18199646 |
| Sen S., Conroy S., Hynes S.O., McMahon J., O'Doherty A., Bartlett J.S., Akhtar Y., Adegbola T., Connolly C.E., Sultan S., Barry F., Katusic Z.S., O'Brien T. Gene delivery to the vasculature mediated by low-titre adeno-associated virus serotypes 1 and 5. J Gene Med. 2008 Feb;10(2):143-51.[PMID: 18067196] PubMed ID: 18067196 |
| Stachler, M.D., Chen, I., Ting, A.Y., and Bartlett, J.S. Site-specific modification of AAV vector particles with biophysical probes and targeting ligands using biotin ligase. Mol Ther. 2008 Jun 17 [Epub ahead of print]. [PMID: 18560418] PubMed ID: 18560418 |
| Ishihara A., Shields K.M., Litsky A.S., Mattoon J.S., Weisbrode S.E., Bartlett J.S., and Bertone A.L. Osteogenic gene regulation and relative acceleration of healing by adenoviral-mediated transfer of human BMP-2 or -6 in equine osteotomy and ostectomy models. J Orthop Res. 2008 Jun;26(6):764-71. [PMID: 18241059] PubMed ID: 18241059 |
| Zachos, T., Diggs, A., Weisbrode, S., Bartlett, J.S., and Bertone, A. Mesenchymal stem cell-mediated gene delivery of bone-morphogenic protein-2 in an articular fracture model. Mol Ther. Epub 2007 May [doi:10.1038/sj.mt.6300192] 2007. |
| Shi, W., Hemminiki, A., and Bartlett, J.S. Capsid modifications overcome low heterogeneous expression of heparan sulfate proteoglycan that limits AAV2-mediated gene transfer and therapeutic efficacy in human ovarian carcinoma. Gyn. Oncol. 67(7):1145-55. 2006. PubMed ID: 16870238 |
| Sharif, F., Hynes, S.O., McMahon, J., Cooney, R., Conroy, S., Dockery, P., Duffy, G., Crowley, J., Kieran, D., Bartlett, J.S., and O’Brien, T. Gene-eluting stents: A comparison of adenoviral and adeno-associated viral gene delivery to the blood vessel wall in vivo. Human Gene Ther. 17(7): 741-750. 2006 PubMed ID: 16839273 |
| Ishihara, A., Bertone, A., Zachos, T.A, and Bartlett, J.S. Relative permissiveness and cytotoxicity of equine chondrocytes, synovial cells, and bone marrow derived mesenchymal stem cells to adenoviral vector gene delivery. Amer J Vet Res. 67(7):1145-55. 2006. PubMed ID: 16817735 |
| Stachler, M., and Bartlett, J.S. Mosaic vectors comprised of modified AAV1 capsid proteins for efficient vector purification and targeting to vascular endothelial cells. Gene Ther. 13:926-931. 2006. PubMed ID: 16482202 |
| Arnold, G.S., Sasser, A.K., Stachler, M., and Bartlett, J.S. Metabolic biotinylation provides a unique platform for the purification and targeting of multiple AAV vector serotypes. Mol Ther. 14(1): 97-106. 2006. PubMed ID: 16624620 |
| Shi, X., Fang, G., Shi, W., and Bartlett, J.S. Insertional mutagenesis at positions 520 and 584 of the adeno-associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors with eliminated heparin-binding ability and introduced novel tropism. Human Gene Ther 17(3):353-361. 2006. PubMed ID: 16544984 |
| Borras, T., Xue, W., Choi, V.W., Samulski, R.J., Bartlett, J.S., Li, G., and Chisolm, S.S. Mechanisms of rAAV transduction in Glaucoma-Associated Human Trabecular Meshwork Cells. J Gene Med. 8:589-602. 2006. PubMed ID: 16506246 |
| Chen, C-L., Jensen, R., Schnepp, B.C., Connell, M.J., Shell, R, Sferra, T.J., Bartlett, J.S., Clark, K.R., and Johnson, P.R. Molecular Characterization of Adeno-Associated Viruses Infecting Children. J Virol. 79: 14781-14792. 2005. PubMed ID: 16282478 |
| Shi, W., and Bartlett, J.S. RGD Inclusion in VP3 Provides Adeno-Associated Virus Type 2(AAV2)-Based Vectors with a Heparan Sulfate-Independent Cell Entry Mechanism. Hum Gene Ther 7(4):515-525. 2003. PubMed ID: 12727115 |
| Zaiss, A-K, Liu, Q., Bowen, G.P., Wong, N.C.W., Bartlett, J.S., and Muruve, D.A. Differential Activation of Innate Immune Responses by Adenovirus and Adeno-Associated Virus Vectors. J. Virol 76(9):4580-4590. 2002. PubMed ID: 11932423 |
| Bartlett, J.S., Wilcher, R. and R.J. Samulski. Infectious Entry Pathway of Adeno-Associated Virus and Adeno-Associated Virus Vectors. J. Virol. 74(6): 2777-2785. 2000 PubMed ID: 10684294 |
| Bartlett, J.S., Prospects for the Development of Targeted Adeno-Associated Virus (AAV) Vector Systems. Tumor Targeting. 4: 143-149. 1999. |
| Bartlett, J.S. Kleinschmidt, J., Boucher, R.C, and Samulski. Targeted Adeno-Associated Virus (AAV) Vector Transduction of Non-permissive Cells Mediated by Bispecific F(ab'g)2 Antibody. Nature Biotech. 17(2): 181-186. 1999. PubMed ID: 10052356 |
| Summerford, C.M., Bartlett, J.S., and R.J. Samulski. aVb5 Integrin: A Co-Receptor for Adeno-Associated Virus Type 2 Infection. Nature Medicine. 5(1): 78-82. 1999. PubMed ID: 9883843 |
| Bartlett, J.S. and Samulski, R.J. Florescent Viral Vectors: A New Technique for the Pharmacological Analysis of Gene Therapy. Nature Med. 4(5): 635-637. 1998. PubMed ID: 9585242 |
| Shi, W., Arnold, G., and Bartlett, J.S. Insertional Mutagenesis of the Adeno-Associated Virus Type 2 (AAV2) Capsid Gene and Generation of AAV2 Vectors Targeted to Alternative Cell-Surface Receptors. Hum. Gene Ther. 12(14) 1697-1711. 2001. PubMed ID: 11560765 |
| Summerford, C.M., Bartlett, J.S. and Samulski, R.J. Adeno-Associated Virus Vectors and Successful Gene Therapy: The Gap is Closing. Gene Ther. Regulation. 1(1): pp-pp. 1999. |
| Teramoto, S., Bartlett, J.S., McCarty, D., Samulski, R.J., and R.C. Boucher. Factors Influencing Adeno-Associated Virus-Mediated Gene Transfer to Human Cystic Fibrosis Airway Epithelial Cells: Comparison with Adenovirus Vectors. J. Virol. 72(11): 8904-8912. 1998. PubMed ID: 9765435 |
| Bartlett, J.S., Samulski, R.J., and T.J. McCown. Selective and Rapid Uptake of Adeno-Associated Virus Type 2 (AAV-2) in Brain. Hum. Gene Ther. 9(8). 1998. PubMed ID: 9625257 |
| Bartlett, J.S., Ramamurthy, L., Sethna, M., Gowen, S., Samulski, R.J., and W.F. Marzluff. Efficient Expression of Protein Coding Genes From the Murine U1 Small Nuclear RNA Promoters. Proc. Natl. Acad. Sci. USA. 93: 8852-8857. 1996. PubMed ID: 8799116 |
|
